193 related articles for article (PubMed ID: 31697049)
1. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine.
Nafziger AN; Arscott KA; Cochrane K; Skobieranda F; Burt DA; Fossler MJ
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):639-650. PubMed ID: 31697049
[TBL] [Abstract][Full Text] [Related]
2. Oliceridine (TRV130), a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model.
Fossler MJ; Sadler BM; Farrell C; Burt DA; Pitsiu M; Skobieranda F; Soergel DG
J Clin Pharmacol; 2018 Jun; 58(6):750-761. PubMed ID: 29412458
[TBL] [Abstract][Full Text] [Related]
3. APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.
Singla NK; Skobieranda F; Soergel DG; Salamea M; Burt DA; Demitrack MA; Viscusi ER
Pain Pract; 2019 Sep; 19(7):715-731. PubMed ID: 31162798
[TBL] [Abstract][Full Text] [Related]
4. Oliceridine: First Approval.
Markham A
Drugs; 2020 Nov; 80(16):1739-1744. PubMed ID: 33025536
[TBL] [Abstract][Full Text] [Related]
5. Oliceridine, a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic Model.
Fossler MJ; Sadler BM; Farrell C; Burt DA; Pitsiu M; Skobieranda F; Soergel DG
J Clin Pharmacol; 2018 Jun; 58(6):762-770. PubMed ID: 29393971
[TBL] [Abstract][Full Text] [Related]
6. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
7. Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain.
Gan TJ; Wase L
Drugs Today (Barc); 2020 Apr; 56(4):269-286. PubMed ID: 32309822
[TBL] [Abstract][Full Text] [Related]
8. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
Fukumura K; Yamada T; Yokota T; Kawasaki A
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):162-174. PubMed ID: 30977959
[TBL] [Abstract][Full Text] [Related]
9. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
11. Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain.
Tan HS; Habib AS
Expert Opin Drug Saf; 2021 Nov; 20(11):1291-1298. PubMed ID: 34370562
[TBL] [Abstract][Full Text] [Related]
12. Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis.
Bergese S; Berkowitz R; Rider P; Ladouceur M; Griffith S; Segura Vasi A; Cochrane K; Wase L; Demitrack MA; Habib AS
Pain Res Manag; 2020; 2020():7492865. PubMed ID: 33163127
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain.
Ayad S; Demitrack MA; Burt DA; Michalsky C; Wase L; Fossler MJ; Khanna AK
Clin Drug Investig; 2020 Aug; 40(8):755-764. PubMed ID: 32583295
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment.
Marbury T; Lawitz E; Stonerock R; Gonzalez M; Jiao J; Breeding J; Haqq C; Verboven P; Stieltjes H; Yu M; Molina A; Acharya M; Chien C; Tran N
J Clin Pharmacol; 2014 Jul; 54(7):732-41. PubMed ID: 24374856
[TBL] [Abstract][Full Text] [Related]
15. Further investigation of the rapid-onset and short-duration action of the G protein-biased μ-ligand oliceridine.
Mori T; Takemura Y; Arima T; Iwase Y; Narita M; Miyano K; Hamada Y; Suda Y; Matsuzawa A; Sugita K; Matsumura S; Sasaki S; Yamauchi T; Higashiyama K; Uezono Y; Yamazaki M; Kuzumaki N; Narita M
Biochem Biophys Res Commun; 2021 Jan; 534():988-994. PubMed ID: 33139013
[TBL] [Abstract][Full Text] [Related]
16. Oliceridine in the treatment of moderate to severe acute pain.
Eleswarpu SS; Habib AS
Pain Manag; 2021 May; 11(3):237-248. PubMed ID: 33455450
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.
Itou M; Fujita T; Inoue K; Uchida N; Takagaki T; Ishii D; Kakuyama H
J Clin Pharmacol; 2020 Oct; 60(10):1397-1403. PubMed ID: 32437025
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
